Jasper Therapeutics

Yahoo Finance • 7 days ago

Evercore ISI Lowers its Price Target on Jasper Therapeutics (JSPR) to $7

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the 8 Most Oversold Penny Stocks to Buy Right Now. On April 1, 2026, Evercore ISI lowered the price target on Jasper Therapeutics, Inc. (NASDAQ:JSPR) to $7 from $12 and maintained an Outp... Full story

Yahoo Finance • 16 days ago

Why UBS Started Jasper Therapeutics (JSPR) at Neutral Despite Progress in Briquilimab

Jasper Therapeutics, Inc. (NASDAQ:JSPR) is one of the penny stocks with the potential to rise 1000percent. UBS initiated coverage of Jasper Therapeutics on March 23, 2026, with a Neutral rating and a $1.50 price target, arguing that compe... Full story

Yahoo Finance • 23 days ago

Here Are Monday’s Top Wall Street Analyst Research Calls: APA Corporation, Cheniere Energy, Crown Castle, Hut 8, MongoDB, Red Rock Resorts, Super Micro Computer, Terawulf, and More

Quick Read Stocks closed lower on Friday for the fourth consecutive week. Soaring oil prices and higher yields on Treasury bonds helped boost selling pressure. With inflation back in the picture and the dollar strengthening, hopes for a r... Full story

Yahoo Finance • 4 months ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change Paranovus Entertain.Tech. Ltd. 115,188,310 0.0734 0.05 0.0528 -0.0252 Be... Full story

Yahoo Finance • 4 months ago

Jasper Therapeutics Reports Positive Results For Briquilimab In Allergic Asthma Phase 1b Study

(RTTNews) - Jasper Therapeutics, Inc. (JSPR), a clinical-stage biotechnology company, on Tuesday reported encouraging preliminary data from its ETESIAN Phase 1b study of subcutaneous briquilimab in adults with allergic asthma. A single su... Full story

Yahoo Finance • 4 months ago

Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from ETESIAN study supports further develop... Full story

Yahoo Finance • 4 months ago

Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-... Full story

Yahoo Finance • 5 months ago

Bragar Eagel & Squire is Investigating Certain Officers and Directors of Driven Brands and Jasper Therapeutics on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

NEW YORK, Nov. 22, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating certain officers and directors Driven Brands Holdings, Inc. (NASDAQ: DRVN) and Jasper Therapeu... Full story

Yahoo Finance • 5 months ago

DEADLINE ALERT for NX, JSPR, and KBR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the d... Full story

Yahoo Finance • 5 months ago

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR

LOS ANGELES, Nov. 18, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securiti... Full story

Yahoo Finance • 5 months ago

Bragar Eagel & Squire, P.C. Reminds Stockholders of Jasper, KBR, Spirit, and Molina of the Upcoming Deadlines and Urges Investors to Contact the Firm

NEW YORK, Nov. 17, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Jasper Therapeutics, Inc.... Full story

Yahoo Finance • 5 months ago

JSPR Investors Have Opportunity to Lead Jasper Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

LOS ANGELES, Nov. 17, 2025 (GLOBE NEWSWIRE) -- The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) f... Full story

Yahoo Finance • 5 months ago

JSPR DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR

NEW YORK, Nov. 16, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates incl... Full story

Yahoo Finance • 5 months ago

JSPR INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC Announces that Jasper Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

NEW YORK, Nov. 14, 2025 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Jasper Therapeutics, Inc. (“J... Full story

Yahoo Finance • 5 months ago

DEADLINE ALERT for NX, JSPR, KBR, RICK: Law Offices of Howard G. Smith Reminds Shareholders of Opportunity to Lead Securities Fraud Class Actions

BENSALEM, Pa., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Law Offices of Howard G. Smith reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies. Investors have until the... Full story

Yahoo Finance • 5 months ago

Jasper Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights – JSPR 

LOS ANGELES, Nov. 14, 2025 (GLOBE NEWSWIRE) -- The DJS Law Group reminds investors of a class action lawsuit against Jasper Therapeutics, Inc. (“Jasper” or “the Company”) (NASDAQ: JSPR) for violations of §§10(b) and 20(a) of the Securiti... Full story

Yahoo Finance • 5 months ago

JSPR DEADLINE ALERT: ROSEN, TOP RANKED INVESTOR RIGHTS COUNSEL, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR

NEW YORK, Nov. 13, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates incl... Full story

Yahoo Finance • 5 months ago

JSPR DEADLINE ALERT: ROSEN, A TOP-RANKED LAW FIRM, Encourages Jasper Therapeutics, Inc. Investors to Secure Counsel Before Important November 18 Deadline in Securities Class Action – JSPR

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates incl... Full story

Yahoo Finance • 5 months ago

Bragar Eagel & Squire, P.C. Reminds Investors of Jasper, KBR, Spirit, and Molina to Contact the Firm About their Rights

NEW YORK, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, reminds investors that class actions have been commenced on behalf of stockholders of Jasper Therapeutics, Inc.... Full story

Yahoo Finance • 5 months ago

Deadline Alert: Jasper Therapeutics, Inc. (JSPR) Shareholders Who Lost Money Urged To Contact Glancy Prongay & Murray LLP About Securities Fraud Lawsuit

LOS ANGELES, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Glancy Prongay & Murray LLP reminds investors of the upcoming November 18, 2025 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who purchased or oth... Full story